Treatment of AIDS still faces multiple challenges such as drug resistance and HIV eradication. Development of new, effective and affordable drugs against HIV is urgently needed. In this study, we developed a world's first web server called Anti-HIV-Predictor (http://bsb.kiz.ac.cn:70/hivpre) for predicting anti-HIV activity of given compounds. This machine learning based web server is rapid and accurate (accuracy >93% and AUC > 0.958), which enables us to screen tens of millions of compounds and discover new anti-HIV agents. We firstly applied the server to screen 1835 approved drugs for anti-HIV therapy. Then the predicted new anti-HIV compounds were experimentally evaluated. Finally, we repurposed 7 approved drugs (cetrorelix, dalbavancin, daunorubicin, doxorubicin, epirubicin, idarubicin and valrubicin) as new anti-HIV agents. The original indication of these drugs is involved in a variety of diseases such as female infertility, acute bacterial infections, leukemia and other cancers. Anti-HIV-Predictor and the 7 repurposed anti-HIV agents provided here demonstrate the efficacy of this strategy for discovery of new anti-HIV agents.
INTRODUCTION
Even 30 years after its discovery, human immunodeficiency virus (HIV) remains a great threat to humans 1, 2 . Acquired immune deficiency syndrome(AIDS), the disease elicited by HIV infection, is considered to be pandemic and represents the greatest global public health crisis 3 . There are an estimated 39 million deaths caused by AIDS since its first recognition 4 . According to the report of the World Health Organization(WHO), there were approximately 37 million people living with HIV at the end of 2014 with 2 million people becoming newly infected with HIV in 2014 globally (http://www.who.int/mediacentre/factsheets/fs360/en/). And 1.2 million people died from HIV-related causes globally in 2014.
Many scientists around the world are committed to finding scientifically proven strategies for HIV prevention and treatment. Recent decades, significant progress has been achieved in the development of vaccines and drugs against HIV infection.
Several clinical trials of anti-HIV vaccines, including RV144, are ongoing 5, 6 . The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency virus (HIV)-1 (referred to as HIV for the rest of this study) infection 7 . The most notable achievement is the transformation of HIV/AIDS from an inevitable death sentence to a chronic illness by the introduction of combination antiretroviral therapy 8, 9 . More than thirty anti-HIV drugs have been approved by the US Food and Drug Administration (FDA) 10 . These drugs act mainly on reverse transcriptase, protease, integrase, CCR5 and so on 11 . Behind the progress, many studies were carried out to discover anti-HIV drug candidates by screening a large number of natural or synthetic compounds. A representative study was the AIDS anti-viral screen program of the National Cancer Institute (NCI), which screened more than 30,000 compounds (https://dtp.cancer.gov/) 12, 13 . After this program, many anti-HIV compounds were reported and deposited in ChEMBL database (ChEMBLdb) 14 . These data are helpful for data mining and developing new tool toward HIV treatment.
Despite considerable progress, treatment of AIDS still faces multiple challenges 15, 16 . To date, no truly effective drug able to eliminate HIV has been developed 17 . Furthermore, HIV is highly variable and can quickly acquire resistance against any drug with which it is confronted 11, 18 . Therefore, there is a constant demand to develop new, effective and affordable anti-HIV drugs. In the past decades, tens of millions of chemical compounds have been deposited in public databases 19 .
Screening these huge databases for new anti-HIV drugs through experimental methods is a tedious, expensive and time-consuming process. The time and money-saving way is that all compounds in the database are firstly filtered by the computational analysis of the anti-HIV potential, then evaluated by experiment.
Therefore, a rapid and accurate computational method is urgently required for predicting anti-HIV activity of chemical compounds.
In this study, we aim to establish a web server to predict anti-HIV activity of given compound and apply the web server to discover new anti-HIV agents through drug repositioning of FDA approved drugs ( Fig. 1) . Drug repositioning is the process of finding new uses outside the scope of the original medical indication for existing drugs 20, 21 . An advantage of drug repositioning lies in the fact that the safety, dosage, and toxicity of existing drugs have already been vetted 22 . Therefore, repurposed candidate drugs can often enter clinical trials much more rapidly than newly developed drugs 23 . Recently, many anti-infectious agents have been discovered to combat pathogens using drug repositioning [24] [25] [26] [27] [28] .
Therefore, in this study, we firstly developed three rapid and accurate computational methods to predict anti-HIV activity of a given compound. Then a web server called Anti-HIV-Predictor (http://bsb.kiz.ac.cn:70/hivpre) is established by integrating the three methods. This web server is free and open to all users. All FDA approved drugs were screened using the web server. Finally, the predicted new anti-HIV compounds were selected for in vitro testing of anti-HIV activity. Using this strategy, we identified cetrorelix, dalbavancin and five anthracycline drugs as new potent anti-HIV agents.
RESULITS

Development of Anti-HIV-Predictor
Workflow for establishing Anti-HIV-Predictor is outlined in Figure 1 .
Anti-HIV-Predictor firstly integrated all the data of anti-HIV activity from ChEMBL and NCI database to construct benchmark dataset. Then, using the benchmark dataset, three prediction models were generated by training, parameter selection and validation. The first model is relative frequency-weighted fingerprint (RFW_FP) based model. RFW_FP is a novel molecular description method which considers the frequency of bit in active and inactive datasets and integrates it to each compound fingerprint. RFW_FP was first used in our previous study and powerful to distinguish the active and inactive compounds for anti-cancer 29, 30 . The other two models are Support Vector Machine (SVM) and Random Forest (RF) models. Last, three models (RFW_FP model, SVM model and RF model) were incorporated to predict anti-HIV activity of chemical compounds. The details for development of Anti-HIV-Predictor are given in the Materials and methods section
Performance of Anti-HIV-Predictor
The overall performance of the RFW_FP, SVM and RF models was quantified by receiver operating characteristic curve (ROC). For each model, the ROC was plotted and the area under the curve (AUC) was calculated ( Fig. 2a ). The ROC curve shows the relation between true positive rate and false positive rate for each threshold of the real-value outputs. The AUC value of the RFW_FP, SVM and RF models are 0.958, 0.974 and 0.977, respectively. All three models achieve AUC value greater than 0.958, which reveals the excellent effectiveness of the models. From the three curves, we can also observe that the three models can effectively identify active anti-HIV compounds with high true-positive rates against low false positive rates.
The classification performance of the models was also assessed in terms of accuracy, precision, recall and F1 score ( Fig. 2b) . As 10 runs of 5-fold cross-validation (CV) method were used, these scores were averaged. Over the ten runs, their standard deviations were also reported. As shown in Figure 2b , the RFW_FP model obtains the statistical average of 93.3%, 86.9%, 90.1%, and 88.5% for accuracy, precision, recall, and F1 score, respectively. The accuracy, precision, recall, and F1 score of SVM model are 96%, 95%, 90.8%, and 92.9%, respectively. RF model performs best with the accuracy of 96% and precision of 99.4%.
Input and output of Anti-HIV-Predictor
Anti-HIV-Predictor is user-friendly and free and open to all users. The only requirement of Anti-HIV-Predictor is the SMILES of the query compound. One or multiple query compounds can be submitted in one request (Fig. 2c) . The total number of input compounds is limited to 100 for each submission.
Anti-HIV-Predictor needs about 60 seconds to load the background data and trained models required for prediction. Therefore, 1-10 compounds requires about 90 seconds, but 100 compounds only requires about 150 seconds. A query with 1-10 compounds requires about 90 seconds, whereas a query with 100 compounds only requires about 150 seconds. After calculated, the output of Anti-HIV-Predictor was shown in Figure   2d . Firstly, the output gives the most similar compound of the query compound. The structures, database links and anti-HIV activities (logEC 50 ) of the matched similar compound were also displayed. Secondly, the output contains some important predicting information, for example, Tanimoto Coefficient score (TC), the Relative Frequency-Weighted Tanimoto Coefficient (RFW_TC), P-value of RFW_TC model, probability estimation by SVM model and RF model. Finally, the output shows the predicting conclusion whether the query compound has anti-HIV activity. One tick represents the query compound is predicted as anti-HIV compound by one of the three models. One cross means that all the three models show no anti-HIV activity for the query compound.
Rapid and accurate computational screen of FDA approved drugs using
Anti-HIV-Predictor
To discover new anti-HIV agents through drug repositioning of FDA approved drugs, 1835 approved drugs with SMILES string were downloaded from DrugBank (http://www.drugbank.ca). Using Anti-HIV-Predictor, all the drugs were screened rapidly by the three models. The results of computational screen are shown in Supplementary Table S1 ).
Experimental confirmation of 15 approved drugs with anti-HIV activity
As the 35 drugs have not been experimental test for anti-HIV activity, it is interesting and worth evaluating their anti-HIV activity by experiment. 28 of these drugs were purchased from CASMART (http://www.casmart.com.cn). Other 7 drugs are not purchased and tested because they are not available or very expensive. Therefore, a total of 28 drugs were evaluated for their anti-HIV activity in vitro with azidothymidine (AZT) as a positive control. The cytotoxicity of these compounds on T cell line C8166 was assessed by MTT colorimetric assay, and 50% cytotoxicity concentration (CC 50 ) was calculated. The inhibitory effect of compounds on HIV replication was measured by the syncytia formation assay and 50% effective concentration (EC 50 ) was calculated as described previously. The assay results of the 28 compounds are presented in Table 1 . For comparison, AZT, the first anti-HIV drug approved by FDA, was utilized as the reference compound. As shown in Table 1, 15 compounds show anti-HIV activity with the EC 50 values ranging from 0.004 to 93.794 μ M. More than half of the tested compounds (15/28) exhibit activity against HIV. It indicates that Anti-HIV-Predictor is a powerful tool for discovering anti-HIV compounds.
Identification of 7 approved drugs as new anti-HIV agents
Among the 15 compounds above, some compounds show serious cytotoxicity and then result in a very low therapeutic index (TI). The drugs with TI value more than 10 were further evaluated their anti-HIV activity by quantification of HIV p24 expression using ELISA method 31 . The best 7 drugs based on the results of cytotoxicity, syncytia formation and p24 quantification assays were displayed in Table 2 and (Fig. 4) . The percent viability at the concentration EC 50 is ranging from 80% to 95% for the five drugs. It indicates that, the anti-HIV activity mainly results from the selective inhibition of HIV replication and less due to toxicity. Their therapeutic index is ranging from 5.9 to 64.8 and far below that of AZT.
DISCUSSION
The failure of 30 years of HIV vaccine development 5, 35 , as well as the prevalence of drug-resistant HIV [36] [37] [38] which is best among the five drugs. Idarubicin inhibits HIV-1 replication at the lowest concentration among the five drugs and close to or better than the positive control drug AZT. The five anthracycline drugs are approved for the treatment of lymphomas, leukemias, Hodgkin's disease, bladder cancer and so on 34 . The HIV-infected patients were more likely to suffer from anal cancer and Hodgkin's lymphoma 42, 43 .
HIV-infected patients with cancer are less likely to receive treatment for some cancers than uninfected people, which may affect survival rate 43, 44 . HIV-infected cancer patients are more likely to die from cancer than uninfected cancer patients. Therefore, the five drugs may be applied to treatment of the HIV-infected patients with cancer.
These patients may benefit from the five drugs Anti-HIV-Predictor predicts anti-HIV activity of compounds based on the benchmark dataset containing active and inactive compounds. The compound with potent anti-HIV activity but less cytotoxicity is expected in the development of anti-HIV drug. Since the cytotoxicity is not taken into account in the current study, some of predicted compounds exhibit high cytotoxicity as shown in Table 1 .
Therefore, Anti-HIV-Predictor is open to improvement. In future, we will consider the cytotoxicity as important factor in the prediction of anti-HIV activity by integrating the NCI-60 growth inhibition data from NCI Development Therapeutics Program (DTP) (https://dtp.cancer.gov/) 45 
METHODS
Construction of benchmark dataset
Anti-HIV activity data were downloaded from ChEMBLdb and NCI. In ChEMBLdb, the compound whose target is "human immunodeficiency virus type 1" and with the activity better than 10 μ mol/L was considered as active compounds. In NCI, the compound with more than 2 replication experiments and with EC 50 less than 10 μ mol/L was considered as active compounds. And the other compounds with EC 50 more than 100μmol/L were consider as inactive compounds. Finally, all compounds in the two databases were integrated by removed the conflict and replicated compounds. This procedure yielded 9584 active and 23998 inactive compounds, respectively. The active and inactive datasets were used as benchmark datasets to generate models to predict anti-HIV activity of chemical compounds. The detailed method of constructing benchmark dataset can be found in Part 1 of Supplementary Material.
RFW_FP model
Firstly, Relative Frequency-Weighted Fingerprint (RFW_FP) was used to calculate the compound fingerprints. RFW_FP was calculated as follows:
where i represents ith Daylight fingerprint. In Daylight theory, each compound contains more than one and less than 1024 fingerprints. RFW_FP(i) is ith relative frequency-weighted fingerprint. Bit(i) is calculated by Pybel 46 α is the amplifying factor. In this study,α was optimized as 0.5
( Supplementary Fig. S2) .
Then, the Relative Frequency-Weighted Tanimoto Coefficient (RFW_TC) between two compounds was calculated as follows:
where RFW_TC(m,n) is RFW_TC between two compounds m and n. S m and S n are the sum of RFW_FPs in compound m and n, respectively. S mn is the sum of the common RFW_FPs between two compounds.
Finally, for each query chemical compounds, the maximum RFW_TC between the query and the active dataset (9584 compounds) was calculated. Then the P-value, based on the maximum RFW_TC, was calculated. As the maximum RFW_TC is less than 1.0 and the maximum RFW_TCs of the inactive compounds have a normal distribution (Supplementary Fig. S3 ), we can calculate the P-value as follows:
where p(χ) is the P-value at the maximum RFW_TC of x; F(χ;μ,σ) is the cumulative function of normal distribution. Using the maximum likelihood method ("fitdist" function in R "fitdistrplus" package 48 Fig. S4) . The detailed method for the selection of kernel function and the penalty parameter C can be found in Part 5 of Supplementary Material.
RF model
The algorithm of random forest is based on the ensemble of a large number of decision trees, where each tree gives a classification and the forest chooses the final classification having the most votes over all the trees in the forest 53 . Random forest, implemented in Scikit-learn 51 , was chosen as classifier with the following settings: (1)
Number of trees was set to 900 (n_estimators =900). This parameter was selected by calculating AUC (Supplementary Fig. S5) . (2) The minimum number of samples to split an internal node was set to 2 (min_samples_split = 2, default setting). For further documentation on the random forest implementation in Scikit-learn, the interested reader is referred to the web site (http://scikit-learn.org).
Performance evaluation
To test performance of Anti-HIV-Predictor, 10 runs 
Compounds, cells and HIV-1 strain
℃ .
Cytotoxicity assays
The cellular toxicity of tested compounds on C8166 was assessed by MTT colorimetric assay 54 . Briefly, 4×10 4 per well C8166 cells were co-incubated with or without a series diluted test compounds. After 3 days of incubation at 37 ℃ , 5% CO 2 , the cell viability was determined by using MTT. Afterward, the 50% cytotoxicity concentration (CC 50 ) was calculated. AZT was used as a positive control.
Inhibition of syncytia formation
The inhibitory effect of samples on acuteHIV-1 NL4-3 infection was measured by the syncytia formation assay as described previously 55 
Inhibition of HIV-1 p24 antigen level in acute infection
For the compounds with TI value greater than 10, the in vitro inhibitory effect of these compounds on HIV-1 replication was further evaluated by quantification of p24 expression. Briefly, 4×10 5 /ml C8166 cells were infected with HIV-1 NL4-3 for 2 hours to allow for viral absorption. It was then washed three times with PBS to remove unadsorbed virus. The cells were plated at 4×10 4 cells/well with or without various concentrations of compounds and incubated in a CO 2 incubator at 37 ℃ with for 72 hours. Supernatants were collected and virus was lysed with 0.5% triton X100. HIV-1 p24 was determined with an in-house ELISA assay described previously 31 . The inhibitory percentage of p24 antigen production was calculated by the OD 490/630 value of compound-treated culture compared to that in infected control culture and EC 50 were calculated.
Code availability
The Python code for predicting anti-HIV activity of given compounds is available from the web server Anti-HIV-Predictor (http://bsb.kiz.ac.cn:70/hivpre). a. The drugs with TI value more than 10 were highlighted with bold fonts. For example, Anti-HIV-Predictor assigns three ticks for the drug nevirapine and a cross for aspirin. which are categorized into three groups: approved anti-HIV drugs (25) , drugs with anti-HIV activity (7) and drugs with no experimental data (35) . 
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